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Abstract
Background: There are no accurate markers that can predict clinical outcome in ulcerative colitis at time of
diagnosis. The aim of this study was to explore a comprehensive data set to identify and validate predictors of
clinical outcome in the first year following diagnosis.
Methods: Treatment naive-patients with ulcerative colitis were included at time of initial diagnosis from 2004 to
2014, followed by a validation study from 2014 to 2018. Patients were treated according to clinical guidelines
following a standard step-up regime. Patients were categorized according to the treatment level necessary to
achieve clinical remission: mild, moderate and severe. The biopsies were assessed by Robarts histopathology index
(RHI) and TNF gene transcripts.
Results: We included 66 patients in the calibration cohort and 89 patients in the validation. Mucosal TNF transcripts
showed high test reliability for predicting severe outcome in UC. When combined with histological activity (RHI)
scores the test improved its diagnostic reliability. Based on the cut-off values of mucosal TNF and RHI scores from
the calibration cohort, the combined test had still high reliability in the validation cohort (specificity 0.99, sensitivity
0.44, PPV 0.89, NPV 0.87) and a diagnostic odds-ratio (DOR) of 54.
Conclusions: The combined test using TNF transcript and histological score at debut of UC can predict severe
outcome and the need for anti-TNF therapy with a high level of precision. These validated data may be of great
clinical utility and contribute to a personalized medical approach with the possibility of top-down treatment for
selected patients.
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Background
Ulcerative colitis (UC) is one of the two main disease en-
tities of inflammatory bowel disease (IBD). UC is a
chronic inflammatory disease believed to result from a
dysregulated immune response caused by a combination
of environmental and genetic factors causing loss of
immunotolerance in the gut [1]. Many patients experi-
ence severe outcomes of disease with significant reduc-
tion in quality of life. The need for surgery is reported in
8 and 9.7% after 5 and 11 years, respectively [2, 3].
Definitions of clinical outcomes and prognosis in IBD
are poorly defined, with little agreement on primary and
secondary endpoints [4]. The IBSEN study is one of the
most well-known prospective studies on clinical out-
comes in UC, where the patients were divided into 4
predefined patterns of disease [2]. In a recently pub-
lished review, the extent of disease and high disease ac-
tivity were predictors of a more severe progression of
disease [5].
The Montréal guidelines classify UC disease activity
into four categories; clinical remission, mild, moderate
and severe disease [6, 7]. Different guidelines for medical
and surgical treatment are available for both UC and CD
in Europe and America, European Crohn’s and Colitis
Organization (ECCO) guidelines and American Gastro-
enterological Association (AGA) clinical care pathway
repectively [8, 9]. Danese et al. have created a modified
algorithm with a medical step-up approach for the treat-
ment of UC with the goal of achieving clinical remission
[10]. In short, 5-ASA and local steroids are used in mild
disease, with additional oral steroids, immunosuppres-
sive and biological therapy in moderate to severe disease,
consecutively. In contrast, a so-called top-down therapy
has previously been documented to induce long term
clinical remission of Crohn’s disease [11].
From a clinical point of view, there is a need to find
good predictive markers at onset of disease that enables
clinicians to individually tailor therapy. There is an in-
creasing interest for a biomarker approach. In various
diseases, such as breast cancer, four gene subtypes of hu-
man epidermal growth factor receptor 2 (HER2) forms
the basis of a molecular reclassification of disease ac-
cording to risk factors [12]. Although there are an in-
creasing number of reports and reviews for clinical and
biochemical biomarkers at onset of disease, none have
been able to predict future clinical outcome with great
certainty [13–18]. In our research group we have pub-
lished reports on mucosal transcript levels of tumor ne-
crosis factor (TNF) as a biomarker for response to and
when to stop anti-TNF thereapy [19–21], However, most
of the studies are of retrospective design and there is a
lack of validated studies of prognostic biomarkers to pre-
dict the clinical outcome in IBD with high reliability.
Moreover, a personalized therapy approach initiated at
the time of disease diagnosis, may have an impact on the
natural course of IBD. This is so far unsettled due to the
lack of long- term studies [22–24].
There is increasing knowledge of the pathophysio-
logical events mediating the mucosal inflammation in
IBD including cytokine and chemokine responses [25,
26]. So far there are few reports on how these crucial
mediators can be used as biomarkers [19–22]. Therefore,
the aims of this study were, first, based on a calibration
cohort of newly diagnosed patients with ulcerative colitis
from 2004 to 2014, to discover potential clinical, bio-
chemical, histological and mucosal gene transcripts to
predict 1 year level of treatment to obtain remission.
Second, to validate these parameters in a cohort study
from 2014 to 2018.
Methods
The main goal of the study was to detect and validate
potential predictors of treatment level 1 year after dis-
ease onset of UC. In principle, to do a proper validation
of a predictor(s) it is general accepted that this should
be a two-step procedure. First, we have to study a cali-
bration (discover) cohort, followed by a study of a valid-
ation cohort to validate the candidate predictors from
the discovery study. Inclusion criteria for both the dis-
covery and validation cohort were patients with newly
diagnosed, treatment- naive UC aged ≥18 years. Patients
were excluded if they were lost to follow in the first year
after diagnosis, patients with severe medical disease
other than UC, pregnancy and lactation; and patients
who first were diagnosed UC but later developed an in-
determinate form of IBD.
In addition to the UC patients with newly diagnosed,
treatment-naïve disease, a group of healthy subjects per-
forming a cancer screening examination with no clinical,
endoscopic or histological signs of intestinal disease
were included as controls.
Cohorts examined
Calibration cohort
Patients attending the Gastrointestinal Unit at the Uni-
versity Hospital of North Norway, Tromsø, Norway,
were recruited from the project Immunopathogenesis in
inflammatory bowel disease in the time period January
2004 –March 2014. Validation cohort: Patients were re-
cruited in the time period March 2014 –March 2018 at-
tending 6 clinical centers in Norway (Gastrointestinal
units at the hospitals of Kirkenes, Hammerfest, Univer-
sity Hospital North Norway, Tromsø, Bodø, Vestre
Viken (Ringerike and Drammen)) as a part of an on-
going prospective study - Advanced Study of Inflamma-
tory Bowel disease (ASIB- study).
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Diagnosis, clinical grading and clinical outcome after 1
year
The clinical grading of UC was based on evaluation of
clinical activity at 1 year. The biopsies were histologically
assessed by an experienced pathologist (SWS) using
Robarts histopathology index (RHI) score [27].
The clinical outcomes of UC are based on the required
treatment level to obtain disease remission, using the
step-up algorithm guidelines ECCO and the three levels
proposed by Danese et al. [10, 28] In this study we used
three disease outcome levels after 1 year; mild, moderate
and severe. These outcomes were defined by the treat-
ment level needed for clinical remission; 5-ASA per oral
or local (mild), need of oral steroids and/or thiopurines
(moderate) and need of anti-TNF and/or surgery (se-
vere) (see Fig. 1). Clinical remission was defined by ul-
cerative colitis clinical score (UCCS) < 2 [29] and/or
calprotectin level < 100 mg/kg according to Feagan et al.
Faecal calprotectin was measured by an ELISA kit from
Calpro Norway (Oslo, Norway).
Tissue samples
Colonic mucosal biopsies were sampled from the region
with the most severe inflammation. In healthy controls,
biopsies were sampled from the sigmoid. Biopsy speci-
mens for RNA extraction were immediately immersed in
RNA later (Qiagen) and stored at room temperature
overnight, then at − 20 °C until RNA isolation.
Cytokine transcript measurements
Total RNA was isolated from patient biopsies using Tri-
zol until July 1, 2008; later the Allprep DNA/RNA Mini
Kit (Qiagen, Hilden, Germany, Cat No: 80204) and the
automated QIAcube instrument (Qiagen, Hilden,
Germany) according to the manufacturer’s recommen-
dations. Quantity and purity of the extracted RNA were
determined using the Qubit 3 Fluorometer (Cat No:
Q33216; Invitrogen by Thermo Fisher Scientific, Wal-
tham, MA, USA). Reverse transcription of the total RNA
was performed using the QuantiTect Reverse Transcrip-
tion Kit (Cat. No: 205314; Qiagen, Hilden, Germany).
Mucosal TNF gene transcript was measured by real-time
PCR procedures previously described in detail [30–33].
Statistics
The following factors were evaluated as predictors: extent
of disease, UCDAI score and endoscopic sub-score, histo-
logical activity score, fecal calprotectin and mucosal cyto-
kine transcripts. All baseline predictors were standardized
and centered for exploring combinations of two variables.
To evaluate predictors of outcome, ROC curves were con-
structed. Optimal cut-off values were picked by maximal
Youden’s J [34]. Test characteristics were derived by con-
fusion matrices and diagnostic odds ratios [35]. A sequen-
tial test for mucosal TNF transcript and RHI score was
constructed: Observations with a positive TNF test were
run in a new ROC analysis for RHI score, which resulted
in a two-step combined model with one cut-off value for
mucosal TNF transcript and another cut-off value for RHI
score following a positive TNF test.
As a global test, Kruskal Wallis one-way ANOVA was
performed, then Mann-Whitney U test with Bonferroni
correction. For categorical values Chi-square test with
Bonferroni correction was utilized.
All statistical analyses were carried out in IBM SPSS Sta-
tistics 24 (IBM Corporation, Armonk, New York, USA).
Results
Healthy controls
Thirty-eight healthy controls were included, 13 females
and 25 men aged 43–69 years. The median TNF value
was 4450 copies/μg mRNA.
Fig. 1 In this and the following figures data from patients with ulcerative colitis at debut of disease are grouped after 1-year treatment level
outcome, Step-up algorithm according to clinical treatment outcomes (mild, moderate, severe). Modified after Danese et al., see ref. [8]
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Calibration cohort
Baseline characteristics and outcome groups
Sixty-six patients were included as a follow up mainly
from an earlier report [19]. At 1 year follow-up patients
were categorized into mild (n = 23), moderate (n = 18)
and severe (n = 25) disease outcomes based on a step-up
treatment level algorithm. In the moderate outcome
group, no patients needed continuous steroid treatment
and two patients were treated with azathioprine. In the
severe outcome group, all patients were on anti-TNF
treatment including one patient that later was in the
need of colectomy. Sixteen patients were on concomi-
tant treatment with azathioprine and one patient on
methotrexate. An overview of baseline characteristics for
each outcome group is shown in Table 1. There were
significant differences between the three treatment
groups for mucosal TNF and UCDAI scores (p < 0.017).
Discovery of potential biomarkers
With three defined treatment outcomes we made two
sets of ROC curves, one set to discriminate between
mild and moderate/severe and one set to discriminate
between mild/moderate and severe. There were no base-
line predictors that showed good test performance for
discriminations between mild and moderate/severe (data
not shown). However, there was a tendency towards in-
creasing concentrations of the mucosal TNF transcripts
with increasing treatment level (Fig. 2a).
Severe outcome
Baseline predictors of severe outcome are shown in Table 1
and Fig. 3 presenting clinical parameters (Calprotectin,
UCDAI, Mayo endoscopic score), RHI score and mucosal
TNF transcripts. Selected predictors including cut off values
are shown in Table 3. Of individual factors, mucosal TNF
transcript had the best test performance with a sensitivity,
specificity and diagnostic odds ratio (DOR) of 0.81, 0.91
and 43 respectively. Clinical data including fecal calprotec-
tin, UCDAI and RHI -score, yielded a high sensitivity but
poor specificity (Table 2, Fig. 3), and therefore a poorer test
performance than mucosal TNF transcript. To increase the
test performance, we then combined mucosal TNF tran-
script and RHI score in a sequential setup: subjects with
mucosal TNF transcript above cut-off were subjected to a
second ROC curve using RHI score as predictor. The com-
bined sequential test of mucosal TNF transcript and RHI
score showed a superior test performance for specificity
and DOR, however lower sensitivity (Table 2). No other
clinical, biochemical, histological or immunological combi-
nations could improve the test performance of prediction
of severe outcome (supplement material Fig. 4).
Validation cohort
Baseline characteristics and outcome groups
At one year follow up patients were categorized into
mild (n = 36), moderate (n = 31) and severe (n = 22) dis-
ease outcomes based on a step-up treatment level
Table 1 Baseline characteristics of patients in the calibration cohort with ulcerative colitis according to one-year treatment outcome
level
Patients groups Mild N = 23 Moderate N = 18 Severe N = 25
Age med (IQR) 41 (35–54) 35 (24–55) 41 (27–54)
Sex
Female 15 (65%) 7 (39%) 9 (36%)
Male 8 (35%) 11 (61%) 16 (64%)
Colonic area involved
Proctitis 9 (39%) 3 (17%) 3 (12%)
Left side 9 (39%) 7 (39%) 10 (40%)
Extensive 5 (22%) 8 (44%) 12 (48%)
Smoking 14 21 12
Current smoker 4 (29%) 2 (17%) 2 (10%)
Non-smoker 10 (71%) 10 (83%) 18 (90%)
Mucosal TNF* 10,500 (4600–11,900) 12,000 (8000–17,200) 26,900 (18700–40,400)
UCDAI med (IQR)* at debut 7 (5–8) 9 (8–12) 12 (9–12)
Calprotectin med (IQR) 590 (400–1100) 790 (470–1540) 2300 (670–2500)
RHI med (IQR) 9 (5–10) 7 (6–10) 9 (7–12)
UCCS score 1-year med (IQR) 0 (0–0) 0 (0–2) 0 (0–2)
Calprotectin 1-year med (IQR) 60 (25–85) 50 (25–100) 25 (0–160)
*p < 0,017 between groups, Mann-Whitney U test with Bonferroni correction
Med (IQR) Median (Interquartile range), RHI Robarts histopathology index. Mucosal TNF in copies/μg RNA: Fecal calprotectin in mg/kg
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algorithm. In the moderate outcome group, no patients
needed continuous steroid treatment and five subjects were
treated with azathioprine. In the severe outcome group, 22
patients were on anti-TNF treatment whereas two of these
patients were later in the need of colectomy. Thirty-eight
healthy controls were included. An overview of baseline
characteristics for each outcome group is shown in Table 3.
There were significant differences between the three treat-
ment groups for mucosal TNF, UCDAI, RHI scores and
fecal calprotectin (Table 3, Fig. 2b).
Validation of predictors of severe outcome
The cut off values from the discovery study (TNF ≥ 18,000,
RHI ≥ 9) were used for test performance. The baseline pre-
dictors of severe outcome presenting mucosal TNF tran-
scripts and RHI score are shown in Table 4. Mucosal TNF
transcript had a test performance with sensitivity, specificity
and DOR of 0.5, 0.9 and 9 respectively. RHI transcript had a
test performance with sensitivity, specificity and DOR of
0.72, 0.69 and 6, respectively. When combined TNF and
RHI the specificity increased to high 0.99, whereas the DOR
was still high as 54. Moreover, the low sensitivity of 0.44
represents most likely the overlapping TNF and RHI score
values to the mild/moderate outcome groups (Table 3).
Discussion
We present a combined discovery study (from 2004) and
a validation study (from 2014) in a prospective design
(the transomic Advanced Study of Inflammatory Bowel
Disease) where clinical, biochemical, histological and
transcript data where retrospectively tested to identify
biomarkers of clinical outcome 1 year after disease diag-
nosis of UC. Mucosal TNF transcripts showed high test
reliability for predicting severe outcome after 1 year in
UC in both studies but was not ideal to discriminate be-
tween mild, moderate and severe disease. Moreover,
when the TNF transcripts were combined with histo-
logical activity (RHI) scores, the test improved its
a
b
Fig. 2 Mucosal TNF transcript in treatment outcome groups and in healthy normal controls in the calibration cohort (a) and the validation
group (b)
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diagnostic reliability. Mucosal cut-off values for TNF
and RHI scores determined in the calibration cohort dis-
played a high test performance with specificity of 0.99
and a diagnostic odds-ratio (DOR) of 54 in the prospect-
ive validation study. Thus, mucosal TNF transcript com-
bined with a histological score at debut of disease can
likely identify patients who experience severe outcomes
during the first year. This is an important step towards
personalizing treatment in IBD and may be used as a cri-
terion for selecting candidates for top-down treatment
of anti-TNF. However, this awaits further studies.
We have tested a broad spectrum of potential factors
that could, alone, or in combinations, predict clinical
outcome in the first year of diagnosis. The clinical out-
comes were defined as the highest treatment level re-
quired for achieving disease remission during the first
year of disease, in a step-up treatment approach. The
broad/wide selection of variables including various com-
binations did not have the necessary precision to dis-
criminate between mild, moderate and severe outcomes.
However mucosal TNF transcript in combination with
the histological RHI score was able to predict, with high
precision, the most severe colitis outcomes needing bio-
logical or surgical treatment, within the first year of dis-
ease. The validated cut-off values (TNF ≥18,000, RHI ≥
9) showed a high specificity to predict severe outcome
and a DOR as high as 54. From a clinical point of view,
these cut–off values indicate a need of anti-TNF therapy
during the first year after diagnosis with high reliability,
and therefore of high clinical value and utility in the
management of IBD/UC. In order to use a biomarker for
selection for top-down treatment, a high PPV is
Table 2 Factors at debut of ulcerative colitis in the calibration cohort to predict severe treatment outcomes at one year of disease
Factors Youden’s J Cut-off value Sensitivity Specificity PPV NPV DOR
TNFa 0,72 ≥18,000 0,81 0,91 0,85 0,89 43
RHIa 0,23 ≥9 0,71 0,52 0,48 0,74 3
Combined TNF RHI 0,57 ≥18,000 and≥ 9 0,57 1 1 0,79 ∞
UCDAI 0,4 ≥9 0,79 0,61 0,54 0,83 6
Mayo subscore 0,45 3 0,72 0,73 0,62 0,81 7
Calprotectin 0,51 ≥2000 0,6 0,91 0,86 0,72 15
Diagnostic odds ratio PPV: Positive predictive value NPV Negative predictive value
a copies/μg mRNA bRobarts histopathology index score
Fig. 3 ROC curves of predictors of severe outcome in calibration cohorte
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necessary to avoid excessive use of biologics. Our pro-
posed biomarker shows a PPV of 0.89 meaning that 9
out of 10 positives will be correctly identified as severe
outcome.
A step-up treatment approach represents well-
established international guidelines [8–10]. One drawback
of this approach is that patients in the severe outcome
group often experience a period of poor response during
the gradual escalation of treatment intensity until an ad-
equate response is obtained. In some cases, one may lose
an important window of opportunity for optimal effect of
biologics leading to permanent structural damage and/or
need of surgery. The impact of early treatment before de-
velopment of severe disease is not completely investigated.
However, the top down approach published by D’Haens
et al. indicated that immunosuppressive therapy was su-
perior to a step-up approach in patients with Crohn’s dis-
ease [36]. Moreover, it is well documented that induction
of treatment to remission reduces later hospitalization,
whereas conflicting results exist for colectomy in two
studies [37, 38].
The use of molecular data from the mucosa represents
a novel approach and is an easily available tool, with
high utility for clinicians to individually tailor therapy in
UC. Endoscopic biopsies are routinely taken at diagnosis
and surveillance of IBD. Thus, the logistics of measuring
mucosal TNF transcript are simple, as biopsies are read-
ily available and samples do not require freezing prior to
analysis [31].
Our study contributes with new knowledge in the sci-
entific field of personalized therapy in UC [15, 16]. We
know that treatment to remission improves long-term
clinical outcome [39, 40]. The main question is: Can a
top-down therapy of the most severe forms of disease
have an effect on the natural course of disease? This
awaits future studies.
The strength of this prospective designed, combined
discovery and validation study is that we have
Table 4 Factors at debut of ulcerative colitis in the validation cohort to predict severe treatment outcomes at one year of disease
based on cut off values from the discovery cohort
Factors Youden’s J Cutt off value Sensitivity Specificity PPV NPV DOR
TNFa 0,40 ≥18,000 0,50 0,90 0,56 0,87 9
RHIb 0,41 ≥9 0,72 0,69 0,38 0,90 6
Combined TNF RHI 0,43 18,000≥ 9 0,44 0,99 0,89 0,87 54
DOR Diagnostic odds ratio, PPV Positive predictive value NPV Negative predictive value
a copies/μg mRNA bRobarts histopathology index score
Table 3 Baseline characteristics of patients with ulcerative colitis in the validation cohort according to one-year treatment outcome
level
Patient groups Mild N = 36 Moderate N = 31 Severe N = 22
Age med (IQR) 36 (24–49) 30 (24–41) 26 (22–47)
Sex
Female 17 (47%) 8 (26%) 10 (46%)
Male 19 (53%) 23 (74%) 12 (54%)
Colonic area involved
Proctitis 5 (14%) 1 (3%) 1 (4%)
Left side 25 (69%) 18 (58%) 10 (46%)
Extensive 6 (17%) 12 (39%) 11 (50%)
Smoking 28 21 12
Current smoker 1 (4%) 2 (10%) 1 (8%)
Non-smoker 27 (96%) 19 (90%) 11 (92%)
Mucosal TNF* 8800 (6100–12,800) 10,500 (7400–13,200) 17,400 (15100–26,800)
UCDAI med (IQR)* at debut 7 (5–9) 9 (8–11) 10 (7–11)
Calprotectin med (IQR)* 570 (200–970) 1000 (340–2000) 1100 (830–1400)
RHI med (IQR)* 6 (2–10) 6 (4–11) 14 (9–27)
UCCS score 1-year med (IQR) 0 (0–0) 0 (0–0) 0 (0–8)
Calprotectin 1-year med (IQR) 40 (25–94) 50 (0–140) 25 (20–60)
*p < 0,017 between groups, Mann-Whitney U test with Bonferroni correction
Med (IQR): median (Interquartile range); RHI: Robarts histopathology index. Mucosal TNF in copies/μg RNA; Fecal calprotectin in mg/kg
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retrospectively searched for and validated biomarkers for
treatment at debut of UC, using a broad search of clin-
ical, histological and analytical factors including mucosal
immune transcripts. Moreover, this is part of the transo-
mic Advanced Study of Inflammatory Bowel disease
(ASIB) study where parallel studies of the epigenome,
transcriptome, proteome and metabolome are ongoing
[33, 41–45]. .This transomic approach at debut of UC
will be performed and correlated to long-term clinical
outcome. Therefore, the upcoming transomic data from
the ASIB study and from several ongoing studies such as
the PREDICTS study will not only search for therapeutic
but also prognostic and natural course biomarkers [17].
The weakness of the study includes the lack of endo-
scopic diagnosis at 1 year, which would have given
insight into endoscopic status and endoscopic remission
rates according to treatment levels. Additionally, the de-
cision to use or not use steroids at time of diagnosis is
dependent on the subjective decision of the clinicians.
This may be one explanation for the small differences
detected between the mild and moderate treatment
group.
Conclusion
The combined information of mucosal TNF transcrip-
tion and histological score at debut of UC can predict
severe outcome and the need for anti-TNF therapy. This
is of great clinical utility and may contribute to a per-
sonalized medicine approach in UC.
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